title: Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.
abstract: Noroviruses account for 96% of viral gastroenteritis cases worldwide, with GII.4 strains responsible >80% of norovirus outbreaks. Histo-blood group antigens (HBGAs) are norovirus binding ligands, and antigenic and preferential HBGA binding profiles vary over time as new GII.4 strains emerge. The capsid P2 subdomain facilitates HBGA binding, contains neutralizing antibody epitopes, and likely evolves in response to herd immunity. To identify amino acids regulating HBGA binding and antigenic differences over time, we created chimeric virus-like particles (VLPs) between the GII.4-1987 and GII.4-2006 strains by exchanging amino acids in putative epitopes and characterized their antigenic and HBGA binding profiles using anti-GII.4-1987 and -2006 mouse monoclonal antibodies (MAbs) and polyclonal sera, 1988 outbreak human sera, and synthetic HBGAs. The exchange of amino acids 393 to 395 between GII.4-1987 and GII.4-2006 resulted in altered synthetic HBGA binding compared to parental strains. Introduction of GII.4-1987 residues 294, 297 to 298, 368, and 372 (epitope A) into GII.4-2006 resulted in reactivity with three anti-GII.4-1987 MAbs and reduced reactivity with four anti-GII.4-2006 MAbs. The three anti-GII.4-1987 MAbs also blocked chimeric VLP-HBGA interaction, while an anti-GII.4-2006 blocking antibody did not, indicating that epitope A amino acids comprise a potential neutralizing epitope for GII.4-1987 and GII.4-2006. We also tested GII.4-1987-immunized mouse polyclonal sera and 1988 outbreak human sera for the ability to block chimeric VLP-HBGA interaction and found that epitope A amino acids contribute significantly to the GII.4-1987 blockade response. Our data provide insights that help explain the emergence of new GII.4 epidemic strains over time, may aid development of norovirus therapeutics, and may help predict the emergence of future epidemic strains.
authors.affiliation: Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina,USA.
authors.forename: Kari
authors.initials: K
authors.lastname: Debbink
authors.forename: Eric F
authors.initials: EF
authors.lastname: Donaldson
authors.forename: Lisa C
authors.initials: LC
authors.lastname: Lindesmith
authors.forename: Ralph S
authors.initials: RS
authors.lastname: Baric
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D001789:Blood Group Antigens / Q000235:genetics / Q000276:immunology; D036022:Capsid Proteins / Q000737:chemistry / Q000235:genetics* / Q000276:immunology*; D018604:Epitope Mapping; D005759:Gastroenteritis / Q000235:genetics / Q000276:immunology* / Q000821:virology; D006801:Humans; D032521:Immunity, Herd; D051379:Mice; D008969:Molecular Sequence Data; D029322:Norovirus / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D016415:Sequence Alignment
chemical_list: D000914:Antibodies, Viral; D001789:Blood Group Antigens; D036022:Capsid Proteins
references.citation: Clin Microbiol Infect. 2006 Jan;12(1):69-74
references.pmid: 16460549
references.citation: J Virol. 2011 Jan;85(1):231-42
references.pmid: 20980508
references.citation: J Infect Dis. 2010 Dec 1;202(11):1649-58
references.pmid: 20979455
references.citation: Mol Biol Evol. 1999 Nov;16(11):1457-65
references.pmid: 10555276
references.citation: Virology. 2008 Sep 30;379(2):324-34
references.pmid: 18692213
references.citation: Nat Rev Immunol. 2004 Mar;4(3):199-210
references.pmid: 15039757
references.citation: J Virol. 1992 Nov;66(11):6527-32
references.pmid: 1328679
references.citation: Bioinformatics. 2003 Aug 12;19(12):1572-4
references.pmid: 12912839
references.citation: Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25
references.pmid: 10511517
references.citation: Arch Virol. 2006 Aug;151(8):1635-41
references.pmid: 16521046
references.citation: Vaccine. 2010 Oct 4;28(42):6852-7
references.pmid: 20723626
references.citation: J Virol. 2007 Sep;81(18):9932-41
references.pmid: 17609280
references.citation: Nature. 2003 Mar 27;422(6930):428-33
references.pmid: 12660783
references.citation: J Virol. 2010 Sep;84(17):8530-8
references.pmid: 20573810
references.citation: J Virol. 2011 Sep;85(17):8635-45
references.pmid: 21715503
references.citation: Pediatr Infect Dis J. 2007 Jan;26(1):46-9
references.pmid: 17195705
references.citation: Emerg Infect Dis. 2008 Aug;14(8):1224-31
references.pmid: 18680645
references.citation: J Virol. 2007 Jun;81(11):5949-57
references.pmid: 17392366
references.citation: Mol Immunol. 2010 Feb;47(5):1132-6
references.pmid: 20047763
references.citation: Gastroenterol Clin North Am. 2006 Jun;35(2):275-90, viii
references.pmid: 16880066
references.citation: J Virol. 2009 Nov;83(22):11890-901
references.pmid: 19759138
references.citation: PLoS Pathog. 2011 Jul;7(7):e1002152
references.pmid: 21811409
references.citation: Science. 2006 Dec 22;314(5807):1898-903
references.pmid: 17185596
references.citation: Science. 1999 Oct 8;286(5438):287-90
references.pmid: 10514371
references.citation: J Gen Virol. 1997 Feb;78 ( Pt 2):291-301
references.pmid: 9018049
references.citation: Arch Virol. 2000;145(2):223-41
references.pmid: 10752550
references.citation: J Virol. 2002 Dec;76(23):12335-43
references.pmid: 12414974
references.citation: Nucleic Acids Res. 2003 Jul 1;31(13):3497-500
references.pmid: 12824352
references.citation: Virol J. 2009 Sep 25;6:150
references.pmid: 19781066
references.citation: J Gen Virol. 2005 Oct;86(Pt 10):2799-2806
references.pmid: 16186235
references.citation: Nat Rev Microbiol. 2010 Mar;8(3):231-41
references.pmid: 20125087
references.citation: PLoS Pathog. 2010 May 06;6(5):e1000884
references.pmid: 20463813
references.citation: Immunol Rev. 2008 Oct;225:190-211
references.pmid: 18837783
references.citation: Vaccine. 2007 Dec 5;25(50):8448-59
references.pmid: 18022293
references.citation: PLoS One. 2008 Jan 23;3(1):e1485
references.pmid: 18213393
references.citation: Clin Infect Dis. 2007 Sep 1;45(5):534-40
references.pmid: 17682985
references.citation: Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):325-30
references.pmid: 21173246
references.citation: J Am Soc Mass Spectrom. 2010 Oct;21(10):1687-98
references.pmid: 20434359
references.citation: J Virol. 2011 May;85(9):4057-70
references.pmid: 21345963
references.citation: J Epidemiol. 2008;18(4):160-6
references.pmid: 18603824
references.citation: J Infect Dis. 2010 Oct 15;202(8):1212-8
references.pmid: 20815703
references.citation: N Engl J Med. 2009 Oct 29;361(18):1776-85
references.pmid: 19864676
references.citation: PLoS Med. 2008 Feb;5(2):e31
references.pmid: 18271619
references.citation: J Virol. 2010 Sep;84(18):9595-607
references.pmid: 20592096
references.citation: Cell. 1982 Dec;31(2 Pt 1):417-27
references.pmid: 6186384
references.citation: J Virol. 2002 Mar;76(6):3023-30
references.pmid: 11861868
references.citation: Proc Biol Sci. 2011 Dec 22;278(1725):3723-30
references.pmid: 21543353
references.citation: Clin Microbiol Infect. 2011 Apr;17(4):640-6
references.pmid: 20731684
references.citation: J Virol. 2009 Jun;83(11):5363-74
references.pmid: 19297483
references.citation: J Clin Microbiol. 2000 Jul;38(7):2595-601
references.pmid: 10878050